Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Scleroderma Patients
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Systemic sclerosis is a chronic autoimmune disease characterized by vascular changes in the
microcirculation (small blood vessels) and progressive fibrosis of the skin and internal
organs. It is believed that vascular changes, expressed early by the Raynaud phenomenon,
precede fibrosis and organic dysfunction. There is no available treatment that reverses the
vascular damage caused by the disease to the moment, although there are several medications
recommended for the relief of manifestations due to vascular injury. Acetylsalicylic acid
(ASA) is one of the medications that can be used for the treatment of vascular injury present
in systemic sclerosis, but still without a fully proven benefit. This study aims to evaluate
the effectiveness of ASA on microcirculation alterations in patients with systemic sclerosis
by performing three exams: periungual panoramic capillary microscopy, videocapillaroscopy and
laser Doppler imaging. In addition, a blood sample will be collected for dosing the following
vascular lesion markers: endothelin-1, von Willebrand factor, thromboxane, and
platelet-derived, endothelial-derived and monocyte-derived microparticles.